BioCentury
ARTICLE | Clinical News

XaraColl regulatory update

November 14, 2016 9:47 PM UTC

Innocoll submitted an NDA to FDA for XaraColl bupivacaine collagen-matrix implants to treat postsurgical pain. The NDA is based on data from the Phase III MATRIX-1 and MATRIX-2 trials (see BioCentury,...

BCIQ Company Profiles

Innocoll Holdings Ltd.